Genesis Therapeutics 和 Gilead Sciences 合作使用 AI 平台 GEMS 开发小分子疗法，吉利德提供 $35M 的预付款和潜在的里程碑付款。 Genesis Therapeutics and Gilead Sciences partner to develop small molecule therapies using AI platform GEMS, with Gilead providing $35M upfront and potential milestone payments.

创世纪治疗与吉利德科学公司已建立战略合作伙伴关系, 以创世纪的AI平台GEMS开发小分子疗法. Genesis Therapeutics and Gilead Sciences have formed a strategic partnership to develop small molecule therapies using Genesis' AI platform, GEMS. Gilead将预付3 500万美元,并可以提出其他目标,而Genesis可能从成功的产品中获得里程碑式付款和特许使用费。 Gilead will provide an upfront payment of $35 million and can nominate additional targets, while Genesis may earn milestone payments and royalties from successful products. 合作的目的是加快药物开发,以达到具有挑战性的目标,Gilead公司保留临床开发和商业化的专属权利。 The collaboration aims to expedite drug development for challenging targets, with Gilead retaining exclusive rights to clinical development and commercialization.